Loading
CT
Cynata Therapeutics Limited Stock: price and insider trades · Australia
Cynata Therapeutics Limited: what insiders have been doing
Cynata Therapeutics Limited is a listed company. Its directors and officers file their transactions with ASX. Between 18 October 2025 and 18 October 2026, 5 insiders published 5 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Insider buying of Cynata Therapeutics Limited has been absent for the past year.
Compared with its exchange (2,222 companies, median 3 filings), a count of 5 filings is above the norm.
Source: insider filings from ASX. Past trades are no guide to future returns.
Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended June 2025 · cache
A$0.01
Analyst consensus
Income statement
EBITDA-A$11.2M
Net income-A$9.4M0.0% margin
Valuation
P/Book0.8x
Beta1.12
Balance sheet & cash
Market capA$2.7M
Free Cash Flow-A$8.8M
Profitability & ownership
ROE-340.8%
ROA-116.5%
% insiders25.0%
% institutions8.0%
Last declaration on 5 July 2026
Declarations5 total
ShareASXASX:2924-03107923-3A696648
ShareASXISIN AU000000CYP7ASX:2924-03107221-3A696537
ShareASXASX:2924-03106630-3A696422
ShareASXASX:2924-03102976-3A695814
5 of 5 declarations
About Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian biopharmaceutical company focused on developing cell therapies. It utilizes its stem cell production platform to address various diseases.
